Callan Family Office LLC Buys Shares of 10,800 Genmab A/S (NASDAQ:GMAB)

Callan Family Office LLC bought a new stake in shares of Genmab A/S (NASDAQ:GMAB) during the 4th quarter, HoldingsChannel reports. The firm bought 10,800 shares of the company’s stock, valued at approximately $225,000.

Other institutional investors have also added to or reduced their stakes in the company. Two Sigma Advisers LP lifted its holdings in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after buying an additional 280,900 shares during the period. ABC Arbitrage SA bought a new position in shares of Genmab A/S during the 4th quarter valued at $3,692,000. AIMZ Investment Advisors LLC bought a new position in shares of Genmab A/S during the 4th quarter valued at $3,525,000. Raymond James Financial Inc. bought a new position in shares of Genmab A/S during the 4th quarter valued at $2,463,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock valued at $1,538,000 after buying an additional 58,048 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 7.8 %

Shares of Genmab A/S stock opened at $20.26 on Wednesday. The company has a market capitalization of $13.41 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 2.65 and a beta of 0.98. The stock’s 50-day simple moving average is $21.29 and its 200-day simple moving average is $22.54. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GMAB shares. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.